Background. EV-D68 is an emerging infectious agent that has been found associated with both mild and severe respiratory diseases and neurological clinical manifestations. Four clades with a number of subclades that can circulate or co-circulate during different periods have been identified. However, molecular evolution of EV-D68 is not known as it is the possible association between specific genetic variants and the development of severe cases. To solve these problems, genetics of strains identified during an outbreak of EV-D68 infection that occurred in Italy during the period March-October 2016 were studied.
Asymptomatic Adults and Children Can Transmit Human Parechoviruses and Enteroviruses to Neonates and Young Infants
Background. Human parechovirus (HPeV) type 3 and enteroviruses (EVs) are the common viruses causing severe diseases in neonates and young infants. Given no specific therapy is currently available and the morbidity and mortality of the diseases are high, understanding the detailed transmission routes is critical for the prevention.
Methods. This prospective study evaluated viral etiologies of neonates and young infants < 4 months suspecting sepsis and/or meningoencephalitis in 2016 in Niigata, Japan. DNA and RNA from serum/cerebrospinal fluid (CSF) were analyzed for HPeVs, EVs, and/or herpes simplex virus using real-time PCR. Bacterial infection was excluded based on blood/CSF culture results and their clinical course of the patients. To investigate the source of infection, we collected stool samples from available family members of the patients regardless of their symptoms. The stool samples were checked for each virus and if they were positive, the VP1 region for HPeVs and VP1/VP4-2 regions for EVs, were sequenced and typed. Furthermore, clinical information on symptomatic family members of HPeVs-and EVs-infected patients was compared.
Results. In total, 23/54 (43%) were positive for HPeVs (12/54, 22%) and EVs (11/54, 20%). Among the available family members for HPeVs and EVs, symptomatic family members were observed 28% (15/54) and 25% (13/53), and their stool samples were positive; 87% (13/15) and 100% (13/13), respectively. For available stool samples from asymptomatic family members, 36% (14/39) was positive for HPeV3 and 50% (20/40) were positive for EVs. Genetic sequence analyses confirmed the identical HPeVs and EVs; 92% (12/13) and 92% (12/13) in symptomatic patients, and 64% (9/14) and 70% (14/20) in asymptomatic patients, respectively. Rhinorrhea was the only symptom commonly observed in symptomatic family members infected with HPeVs (12/13, 92%) compared with those infected with EVs (4/13, 31%) (P = 0.004).
Conclusion. Symptomatic, and even asymptomatic children and adults can be a source of HPeVs-and EVs-infected neonates and young infants. Careful hand hygiene and other standard precaution may contribute to decrease the risk of the transmission during the outbreak of HPeV3 and EVs.
Disclosures. (RSV) is an established cause of serious lower respiratory tract disease in infants and young children. To better describe currently circulating strains, monitor their evolution and characterize the patient populations, the Methods. OUTSMART included 14 labs in 4 US regions and Puerto Rico that provided RSV-positive samples and matching demographic data during Dec 2015 to Mar 2016 for subtyping and descriptive analyses. To gauge the representativeness of the OUTSMART patient sample, results were compared with the Nationwide Emergency Department Sample (NEDS) and the National Inpatient Sample (NIS).
Results. Participating labs reported 10,304 RSV-positive samples (10.9%) out of 94,710 tested, of which 525 samples were submitted for further analyses. The majority of samples came from children ≤ 2 years: 1-3 months (17.5%), 4-6 months (13.7%), 7-12 months (21.9%), and 1-2 years (17.5%). The distribution of samples from males (53.0%) and females (47.0%) were similar. Of those with determined RSV subtype (n = 392; 74.7%), 62.8% were subtype A and 38.3% were subtype B. Of the two co-circulating subtypes, A was more prevalent through age 5 while B was more common in those ages 6+. Hospitalizations >24 hours occurred among 36.6% of patients. The proportions of patients with subtype A were similar among hospitalized vs. non-hospitalized patients (62.3% and 63.2%, respectively). Subtype A predominated in all 4 regions, with the highest proportions of subtype A in the Midwest (65.1%) and the West (64.8%). Most RSV-positive samples were collected February-March. For all databases, the largest disease burden was among those <1 year old (OUTSMART: 45.1%, NEDS 62.3%, NIS 62.7%), followed by the 1-2 year age group (OUTSMART: 27.6%, NEDS 26.9%, NIS 21.8%). The databases were also similar by gender (% male-OUTSMART: 53.0%, NEDS 53.9%, NIS 53.9%).
Conclusion. The OUTSMART program characterizes circulating RSV strains and monitors their temporal and geographic evolution in the US to inform the development of anti-RSV monoclonal antibodies and vaccines.
